SOURCE: Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc.

November 04, 2015 16:30 ET

Esperion Therapeutics Announces Two Oral Presentations for ETC-1002 at the American Heart Association Scientific Sessions 2015

Company to Host Webcast on Tuesday, November 10, 2015 at 7:45 a.m. Eastern Time

ANN ARBOR, MI--(Marketwired - November 04, 2015) - Esperion Therapeutics, Inc. (NASDAQ: ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with hypercholesterolemia, today announced Christie Ballantyne, MD, professor at Baylor College of Medicine and director of Houston Methodist DeBakey Heart and Vascular Center, will present full results from the Phase 2b ETC-1002-009 clinical study during the American Heart Association (AHA) Scientific Sessions 2015. The abstract, "ETC-1002 Incrementally Lowers Low Density Lipoprotein Cholesterol in Patients with Hypercholesterolemia Receiving Stable Statin Therapy," will be presented in an oral presentation on Monday, November 9, 2015 at 6:30 p.m. Eastern Time at the Orange County Convention Center, Orlando, FL in Room W205. Stephen Pinkosky, senior scientist and head of translational research at Esperion Therapeutics, will present the abstract, "Identification of a Tissue Specific Very Long Chain Acyl-CoA Synthetase Involved in the Inhibition of ATP-Citrate Lyase (ACL) by ETC-1002: A Novel Mechanism for Cholesterol Biosynthesis Inhibition in the Liver," in an oral presentation on Monday, November 9, 2015 at 11:45 a.m. Eastern Time in Room W303.

Conference Call and Webcast Information

Esperion will host a live webcast briefing on Tuesday, November 10, 2015 at 7:45 a.m. Eastern Time to provide full clinical results of the Phase 2b ETC-1002-009 study and new data on ATP Citrate Lyase inhibition, the mechanism of action for LDL-C lowering for ETC-1002. The webcast can be accessed by dialing (877) 831-3840 (domestic) or (253) 237-1184 (international) five minutes prior to the start and providing access code 68066683. A live, listen-only webcast of the conference call can be accessed on the investor relations section of the Esperion website at www.esperion.com. A webcast replay of the call will be available approximately two hours after completion of the call and will be archived on the Company's website for 90 days following the event.

About ETC-1002-009

The 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel group Phase 2b study evaluated the efficacy and safety of ETC-1002 versus placebo when added to low- and moderate-dose stable statin therapy in patients with hypercholesterolemia -- also known as the "add-on to statin" study. Secondary objectives were to characterize the dose response; assess the effect of ETC-1002 on additional lipid and cardiometabolic risk markers, including hsCRP; and characterize the safety and tolerability of ETC-1002. A total of 134 patients with hypercholesterolemia were washed out of any lipid-regulating therapies, except atorvastatin, simvastatin, rosuvastatin, or pravastatin. Forty-three* patients received ETC-1002 120 mg; 45 patients received ETC-1002 180 mg; 45 patients received placebo.

*One patient was randomized but did not receive study drug.

Esperion's Commitment to Cardiometabolic Disease

Esperion is committed to improving the lives of patients with hypercholesterolemia by developing therapies to lower LDL-C. Esperion scientists discovered ETC-1002 and the LDL-C lowering therapy is in late stage development. Esperion plans to develop both ETC-1002 and a fixed dose combination of ETC-1002 and ezetimibe with a particular focus on patients with hypercholesterolemia who are considered intolerant of statin therapy. It is estimated that approximately 10% of patients who are prescribed statins, 3.5 million patients in the U.S., are considered statin intolerant.

About Esperion Therapeutics

Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, LDL-C lowering therapies for the treatment of patients with hypercholesterolemia. ETC-1002 (bempedoic acid), the Company's lead product candidate, is an inhibitor of ATP Citrate Lyase, a well-characterized enzyme on the cholesterol biosynthesis pathway. ETC-1002 inhibits cholesterol synthesis, decreases intracellular cholesterol, up-regulates LDL-receptors, and causes increased LDL-C clearance and reduced plasma levels of LDL-C. For more information, please visit www.esperion.com and follow us on Twitter at https://twitter.com/EsperionInc.

Contact Information